Compare Stocks: MTNB, MRVFF, PHXM, and MDCX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDCX Medicus Pharma	$0.17 +0.8%	$0.27	$0.14 ▼ $3.05	$10.78M	0.12	10.00 million shs	2.97 million shs
MRVFF Nuvo Pharmaceuticals	$0.98	$0.98	$0.42 ▼ $1.25	$11.17M	0.98	11,250 shs	N/A
MTNB Matinas Biopharma	$0.16 -1.6%	$0.24	$0.15 ▼ $2.14	$2.39M	1.7	838,076 shs	425,929 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDCX Medicus Pharma	+0.82%	+5.78%	-34.97%	-62.28%	-92.86%
MRVFF Nuvo Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MTNB Matinas Biopharma	-1.60%	-13.30%	-33.44%	-73.44%	-90.28%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDCX Medicus Pharma	$0.17 +0.8%	$0.27	$0.14 ▼ $3.05	$10.78M	0.12	10.00 million shs	2.97 million shs
MRVFF Nuvo Pharmaceuticals	$0.98	$0.98	$0.42 ▼ $1.25	$11.17M	0.98	11,250 shs	N/A
MTNB Matinas Biopharma	$0.16 -1.6%	$0.24	$0.15 ▼ $2.14	$2.39M	1.7	838,076 shs	425,929 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDCX Medicus Pharma	+0.82%	+5.78%	-34.97%	-62.28%	-92.86%
MRVFF Nuvo Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MTNB Matinas Biopharma	-1.60%	-13.30%	-33.44%	-73.44%	-90.28%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDCX Medicus Pharma	2.50	Moderate Buy	$9.00	5,132.56% Upside
MRVFF Nuvo Pharmaceuticals	0.00	N/A	N/A	N/A
MTNB Matinas Biopharma	0.00	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MTNB, MRVFF, PHXM, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
MRVFF Nuvo Pharmaceuticals	$54.98M	0.20	$0.09 per share	11.09	($0.80) per share	-1.22
MTNB Matinas Biopharma	$1.10M	2.14	N/A	N/A	$0.75 per share	0.21
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)
MRVFF Nuvo Pharmaceuticals	-$25.70M	-$0.12	N/A	N/A	N/A	20.88%	-1,996.22%	14.25%	N/A
MTNB Matinas Biopharma	-$10.35M	-$3.89	N/A	N/A	N/A	N/A	-166.11%	-102.20%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MTNB, MRVFF, PHXM, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	MTNB Matinas Biopharma	N/A	-$0.21	N/A	-$0.21	N/A	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MRVFF Nuvo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDCX Medicus Pharma	N/A	1.57	1.57
MRVFF Nuvo Pharmaceuticals	9.97	2.11	1.77
MTNB Matinas Biopharma	N/A	0.85	0.85
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDCX Medicus Pharma	N/A
MRVFF Nuvo Pharmaceuticals	N/A
MTNB Matinas Biopharma	11.77%
PHXM PHAXIAM Therapeutics	0.40%

Insider Ownership

Company	Insider Ownership
MDCX Medicus Pharma	8.10%
MRVFF Nuvo Pharmaceuticals	7.00%
MTNB Matinas Biopharma	4.60%
PHXM PHAXIAM Therapeutics	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDCX Medicus Pharma	16	63.18 million	58.06 million	N/A
MRVFF Nuvo Pharmaceuticals	100	11.40 million	10.60 million	Not Optionable
MTNB Matinas Biopharma	30	14.69 million	14.02 million	N/A
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data

MTNB, MRVFF, PHXM, and MDCX Headlines

Recent News About These Companies

PHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJ

July 18, 2025 | wsj.com

Phaxiam Therapeutics SA (PHXM) Stock Forums - Investing.com

June 27, 2025 | investing.com

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

June 18, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

June 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

June 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

May 23, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure

May 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Update on the Receivership Procedure

April 25, 2025 | finance.yahoo.com

Phaxiam Therapeutics S.A.

March 28, 2025 | wsj.com

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

March 15, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

March 6, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

March 6, 2025 | finance.yahoo.com

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

January 31, 2025 | businesswire.com

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

January 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

January 7, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

December 30, 2024 | finance.yahoo.com

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

November 27, 2024 | globenewswire.com

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

November 18, 2024 | globenewswire.com

Phaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | finanznachrichten.de

PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, MRVFF, PHXM, and MDCX Company Descriptions

Medicus Pharma NASDAQ:MDCX

$0.17 +0.00 (+0.82%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$0.17 0.00 (0.00%)

As of 09/18/2026 07:46 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Nuvo Pharmaceuticals OTCMKTS:MRVFF

$0.98 0.00 (0.00%)

As of 03/16/2023

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Matinas Biopharma NYSEAMERICAN:MTNB

$0.16 0.00 (-1.60%)

As of 09/18/2026 04:10 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 09/18/2026

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTNB, MRVFF, PHXM, and MDCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTNB, MRVFF, PHXM, and MDCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTNB, MRVFF, PHXM, and MDCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, MRVFF, PHXM, and MDCX Company Descriptions

Medicus Pharma NASDAQ:MDCX

Nuvo Pharmaceuticals OTCMKTS:MRVFF

Matinas Biopharma NYSEAMERICAN:MTNB

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTNB, MRVFF, PHXM, and MDCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTNB, MRVFF, PHXM, and MDCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTNB, MRVFF, PHXM, and MDCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, MRVFF, PHXM, and MDCX Company Descriptions

Medicus Pharma NASDAQ:MDCX

Nuvo Pharmaceuticals OTCMKTS:MRVFF

Matinas Biopharma NYSEAMERICAN:MTNB

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools